Biotechnology Value Fund L P's Form 4 filing
Cullinan Therapeutics, Inc. (CGEM) · filed May 16, 2022
- Accession no.
- 0000921895-22-001689
- Filed
- May 16, 2022, 7:34 PM ET
- Trade date
- May 12-13, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market purchases total $10.1M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | Other: See Explanation of Responses |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Other: See Explanation of Responses |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | Other: See Explanation of Responses |
| BVF II GP LLCCIK 0001803806 | Other: See Explanation of Responses |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2022 | Common Stock | PPurchaseAcquired | +542,999 | $9.06 | +$4,919,570.94 | 3,599,615 | Direct | |
| May 13, 2022 | Common Stock | PPurchaseAcquired | +53,598 | $9.14 | +$489,617.73 | 3,653,213 | Direct | |
| May 12, 2022 | Common Stock | PPurchaseAcquired | +457,001 | $9.06 | +$4,140,429.06 | 2,653,241 | Direct | |
| May 13, 2022 | Common Stock | PPurchaseAcquired | +38,558 | $9.14 | +$352,227.33 | 2,691,799 | Direct | |
| May 13, 2022 | Common Stock | PPurchaseAcquired | +17,744 | $9.14 | +$162,091.44 | 319,415 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.